Abstract
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow, UK
Highlights
Current consensus about treatment of HIV infection is that HAART must include two nucleoside reverse transcriptase inhibitors plus a third drug
There is a lot of interest about changing the basic structure of the antiretroviral regimen so we can be able to use nucleoside-sparing regimens
In patients who have already achieved suppression it is possible that a boosted protease inhibitor used as monotherapy might be all what is needed to maintain suppression
Summary
Current consensus about treatment of HIV infection is that HAART must include two nucleoside reverse transcriptase inhibitors plus a third drug (one non-nucleoside reverse transcriptase inhibitor, a boosted protease inhibitor, an integrase strand transfer inhibitor and possibly a CCR5 inhibitor). The state of PI monotherapy and NRTIsparing therapy From Tenth International Congress on Drug Therapy in HIV Infection Glasgow, UK.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
